ProKidney (NASDAQ:PROK) Sees Strong Trading Volume - Time to Buy?

Key Points

• Unusual trading activity: About 1,193,076 shares traded (a 36% jump from the prior session) as the stock hovered near $1.93, up roughly 1.8% intraday, with 50‑day/200‑day SMAs at $2.04 and $2.35.
• Mixed analyst outlook but bullish consensus: The average rating is a "Moderate Buy" with a consensus price target of $7.40, though individual notes range from Jefferies' "Strong Buy" and HC Wainwright's $12 target to sell ratings from Weiss and Wall Street Zen.
• Financials and ownership: ProKidney has a market cap of ~$599M and a negative P/E (-3.82); it posted EPS of -$0.14 (beating estimates) on $0.23M revenue, with sell‑side forecasts of -0.57 EPS for the year and ~51.6% institutional ownership.

ProKidney Corp. (NASDAQ:PROK - Get Free Report) shares saw unusually-high trading volume on Monday . Approximately 1,193,076 shares were traded during mid-day trading, an increase of 36% from the previous session's volume of 875,623 shares.The stock last traded at $1.9250 and had previously closed at $1.95.

Wall Street Analysts Forecast Growth

A number of equities research analysts have commented on the company. HC Wainwright started coverage on ProKidney in a research report on Tuesday, December 16th. They set a "buy" rating and a $12.00 price objective for the company. Wall Street Zen lowered shares of ProKidney from a "hold" rating to a "sell" rating in a research report on Saturday, March 21st. Jefferies Financial Group raised shares of ProKidney to a "strong-buy" rating in a research report on Wednesday, March 18th. Finally, Weiss Ratings reiterated a "sell (d-)" rating on shares of ProKidney in a research note on Thursday, January 22nd. One investment analyst has rated the stock with a Strong Buy rating, four have issued a Buy rating, one has given a Hold rating and two have assigned a Sell rating to the stock. According to MarketBeat, the company currently has an average rating of "Moderate Buy" and a consensus price target of $7.40.

ProKidney Trading Up 1.8%

The firm has a 50-day simple moving average of $2.04 and a two-hundred day simple moving average of $2.35. The company has a market capitalization of $599.30 million, a price-to-earnings ratio of -3.82 and a beta of 1.84.

ProKidney (NASDAQ:PROK - Get Free Report) last issued its quarterly earnings data on Wednesday, March 18th. The company reported ($0.14) earnings per share for the quarter, beating the consensus estimate of ($0.16) by $0.02. The business had revenue of $0.23 million for the quarter, compared to the consensus estimate of $0.00 million. On average, sell-side analysts forecast that ProKidney Corp. will post -0.57 earnings per share for the current year.

Hedge Funds Weigh In On ProKidney

Several hedge funds have recently bought and sold shares of PROK. Cetera Investment Advisers acquired a new stake in shares of ProKidney in the fourth quarter worth about $28,000. Zullo Investment Group Inc. bought a new position in shares of ProKidney in the 3rd quarter valued at approximately $28,000. AQR Capital Management LLC raised its stake in shares of ProKidney by 106.4% in the 1st quarter. AQR Capital Management LLC now owns 52,570 shares of the company's stock valued at $46,000 after acquiring an additional 27,098 shares in the last quarter. EntryPoint Capital LLC acquired a new stake in ProKidney in the 4th quarter worth approximately $65,000. Finally, Hudson Bay Capital Management LP bought a new stake in ProKidney during the fourth quarter worth approximately $101,000. 51.59% of the stock is owned by institutional investors and hedge funds.

About ProKidney

ProKidney, Inc NASDAQ: PROK is a clinical-stage biotechnology company focused on developing cell-based therapies for kidney diseases. The company’s research and development activities center on harnessing human-derived proximal tubule cells to address conditions such as acute kidney injury (AKI) and chronic kidney disease (CKD). By targeting the underlying cellular mechanisms of renal injury and dysfunction, ProKidney aims to offer novel regenerative medicine approaches that go beyond current supportive care options.

ProKidney’s lead programs utilize proprietary methods for isolating and expanding renal epithelial cells to create injectable therapeutic products.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.